Bevacizumab, an anti-vascular endothelial growth factor (VEGF) therapy, has been explored for treating GBM due to the role of hypervascularity in promoting GBM progression and immune evasion through hypoxia [87,88,89]. This evidence concerns the gene VEGFA and glioblastoma.